You are here: Industry Insights > NT-300

News List

NT-300 tablets show promise in Phase III COVID-19 trial europeanpharmaceuticalreview
April 19, 2021
Initial results suggest NT-300 (nitazoxanide extended-release tablets, 300mg) reduces progression to severe illness in mild to moderate COVID-19 patients.
Romark Initiates Trial of NT-300 for COVID-19 americanpharmaceuticalreview
August 17, 2020
Romark announced the initiation of a Phase 3 clinical trial of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19.
Phase III trial to study NT-300 as COVID-19 treatment initiated europeanpharmaceuticalreview
August 17, 2020
A Phase III trial to investigate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19 has begun.
Romark Initiates Phase 3 Clinical Trials Of NT-300 for COVID-19 americanpharmaceuticalreview
April 30, 2020
Romark will initiate two clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets) for prevention of COVID-19 and other viral respiratory illnesses in high-risk populations.
Romark Initiates Trials of NT-300 for COVID-19 Prevention contractpharma
April 28, 2020
In cell cultures, the active ingredient in NT-300, nitazoxanide, inhibits replication of a broad range of respiratory viruses, including SARS-CoV-2.